

PERSONAL INFORMATION **Patrick Schöffski**

## WORK EXPERIENCE

- 
- 2002–2004 **Head of solid tumor service**  
, Dpt. of Haematology and Oncology, MHH, Hannover (Germany)
  
  - 2002–2004 **Consultant, interdisciplinary radiation oncology ward**  
MHH, Hannover (Germany)
  
  - 2004–2005 **Staff member Department of Clinical Oncology and Radiotherapy**  
University Hospitals Leuven (UZL), Catholic University Leuven (KUL), Leuven (Belgium)
  
  - 2005–Present **Head of Department of General Medical Oncology**  
UZL, Leuven (Belgium)
  
  - 2005–Present **Section Head of Experimental Oncology, Department of Oncology**  
KUL, Leuven (Belgium)
  
  - 2005–Present **Laboratory of Experimental Oncology (LEO)**  
KUL, Leuven (Belgium)
  
  - 2005–2010 **coordinator**  
Cell Phase I Studies, Leuven Cancer Institute, UZL, Leuven (Belgium)

## EDUCATION AND TRAINING

- 
- 1990– **MD**  
Hannover Medical School (MHH), Hannover
  
  - 1990–1992 **Master studies in public health, epidemiology, preventive medicine and health economics**  
Dpt. of Social Medicine/Public Health, MHH, Hannover, Germany
  
  - 1992– **Definitive license to practice as physician**  
Landesprüfungsamt, Hannover, Germany  
Academic degree “Master of Public Health”, MHH, Hannover, Germany
  
  - 1995– **Certification in radiation safety**
  
  - 1995– **Certification in genetic engineering safety**
  
  - 1997– **Board certification for internal medicine**  
“Arzt für Innere Medizin/Internist”, Ärztekammer Niedersachsen, Hannover, Germany
  
  - 1998– **Board certification for haematology and oncology**

“Arzt für Hämatologie und Internistische Onkologie”, Ärztekammer Niedersachsen, Hannover, Germany

- 2000– European certification in medical oncology
- 2001– Graduation as university lecturer (Habilitation)
- 2001–2004 „Hochschuldozentur“, MHH, Hannover, Germany
- 2004– Academic degree “Ausserplanmässiger Professor”, MHH, Hannover

## ADDITIONAL INFORMATION

### Expertise

### Publications Peer reviewed scientific publications

Bechter O, Schöffski P. Make your best BET the emerging role of BET inhibitor treatment in malignant tumors. *Pharmacol Ther.* 2020;Jan 10:107479. Doi: 10.1016/j.pharmthera.2020.107479. [Epub ahead of print].

Nemunaitis J, Bauer S, Blay JY, Choucair K, Gelderblom H, George S, Schöffski P, von Mehren M, Zalcberg J, Achour H, Ruiz-Soto R, Heinrich MC. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. *Future Oncol.* 2019 [Epub ahead of print].

Antonia SJ, Balmanoukian A, Brahmer J, Ou SHI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu ST, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabro L, Weiss J, Segal NH. Clinical activity, tolerability, and long-term follow-up of durvalumab in patients with advanced NSCLC. *J. Thoracic Oncology.* 2019;14(10):1794-1806.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, Mc Arthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med.* 2019;381(16):1535-1546.

Vaishampayan U, Schöffski P, Ravaud A, Borel C, Peguero J, Chaves J, Morris JC, Kotecki N, Smakal M, Zhou D, Guenther S, Bajars M, Gulley JL. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN solid tumor trial. *J Immunother Cancer.* 2019;7(1):275.

Cornillie J, Wozniak A, Van Renterghem B, Van Winkel N, Wellens J, Gebreyohannes YK, Debiec-Rychter M, Sciot R, Hompes D, Schöffski P. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. *BMC Cancer.* 2019;19:724.

Amirnasr A, Gits CMM, van Kuijk PF, Smid M, Vriends ALM, Rutkowski P, Sciot R, Schöffski P, Debiec-Rychter M, Sleijfer S, Wiemer EAC. Molecular comparison of imatinib-naïve and resistant gastro-intestinal stromal tumors: differentially expressed microRNAs and mRNAs. *Cancers.* 2019;11:882.

Le Cesne A, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, Hohenberger P, Gelderblom H. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. *BMC Cancer.* 2019;19:794.

Verbiest A, Renders I, Caruso S, Couchy G, Job S, Laenen A, Verkarre V, Rioux-Leclercq N, Schöffski P, Vano Y, Elaidi RT, Lerut E, Albersen M, Oudard S, Fridman WH, Sautès-Fridman C, Albigès L, Wozniak A, Zucman-Rossi J, Beuselinck B. Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. *Clin Genitourin Cancer.* 2019;17(10):e981-e994.

Antonia SJ, Balmanoukian A, Brahmer J, Ou SH, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu ST, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis H, Calabro L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebalatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH. Clinical activity, tolerability, and long-term follow-up of Durvalumab in patients with advanced NSCLC. *J Thorac Oncol.* 2019;14(10):1794-1806

- Younger E, Ballman K, Lu Y, Pápai Z, Van Tine BA, Attia S, Schöffski P, Reinke D, Tap WD, Jones RL. Subgroup analysis of older patients treated within the randomized phase 3 doxorubicin versus doxorubicin plus evofosfamide (SARC021) trial. *J Geriatr Oncol*. 2019 May 21. Pii: S1879-4068(18)30464-8. doi: 10.1016/j.jgo.2019.05.008. [Epub ahead of print]
- Cornillie J, Wozniak A, Li H, Wang Y, Boeckx B, Gebreyohannes YK, Wellens J, Vanleeuw U, Hompes D, Stas M, Sinnaeve F, Wafa H, Lambrechts D, Debiec-Rychter M, Sciot R, Schöffski P. Establishment and characterization of histologically and molecularly stable soft tissue sarcoma xenograft models for biological studies and preclinical drug testing. *Mol Cancer Ther*. 2019;18(6):1168-1178.
- Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, Jia Y, Maki RG. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. *Br J Cancer*. 2019;120(11):1026-1032.
- Jones RL, Chawla SP, Attia S, Schöffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. *Cancer*. 2019;125(14):2445-2454.
- Cornillie J, Wozniak A, Li H, Gebreyohannes YK, Wellens J, Hompes D, Debiec-Rychter M, Sciot R, Schöffski P. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harbouring MDM2 amplification. *Clin Transl Oncol*. 2019 doi: 10.1007/s12094-019-02158-z. [Epub ahead of print]
- Isfort I, Cyra M, Elges S, Kailayangiri S, Altwater B, Rossig C, Steinestel K, Grünwald I, Huss S, Esseling E, Mikesch JH, Hafner S, Simmet T, Wozniak A, Schöffski P, Larsson O, Wardelmann E, Trautmann M, Hartmann W. SS18-SSX-dependent YAP/TAZ Signaling in Synovial Sarcoma. *Clin Cancer Res*. 2019;25(12):3718-3731.
- Segal N, Ou SH, Balmanoukian A, Fury M, Massarelli E, Brahmer JR, Weiss J, Schöffski P, Antonia SJ, Massard C, Zandberg DP, Khleif SN, Xiao F, Rebelatto MC, Steele KE, Robbins PB, Angra N, Song X, Abdullah S, Butler M. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort. *Eur J Cancer*. 2019;109:154-161.
- Gebreyohannes YK, Burton EA, Wozniak A, Matusow B, Habets G, Wellens J, Cornillie J, Lin J, Nespi M, Wu G, Zhang C, Bollag G, Debiec-Rychter M, Sciot R, Schöffski P. PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. *Clin Exp Med*. 2019;19(2):201-210.
- Péron J, Marreaud S, Staelens D, Raveloarivahy T, Nzokirantevye A, Flament J, Steuve J, Lia M, Collette L, Schöffski P. A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial. *Eur J Cancer*. 2019;109:192-195.
- Pulkka OP, Gebreyohannes YK, Wozniak A, Mpindi JP, Tynninen O, Icaý K, Cervera A, Keskitalo S, Murumägi A, Kuleskiy E, Laaksonen M, Wennerberg K, Varjosalo M, Laakkonen PM, Lehtonen R, Hautaniemi S, Kallioniemi O, Schöffski P, Sihto H, Joensuu H. Anagrelide for gastrointestinal stromal tumor. *Clin Cancer Res*. 2019;25(5):1676-1687.
- Vanmechelen M, Lambrechts D, Van Brussel T, Verbiest A, Couchy G, Schöffski P, Dumez H, Debruyne PR, Lerut E, Machiels JP, Richard V, Albersen M, Verschaeve V, Oudard S, Méjean A, Wolter P, Zucman-Rossi J, Beuselinck B. Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. *Clinical Genitourin Cancer*. 2019;17(2):e235-e246.
- Werbrouck E, Bastin J, Lambrechts D, Verbiest A, Van Brussel T, Lerut E, Machiels JP, Verschaeve V, Richard V, Debruyne PR, Decallonne B, Schöffski P, Bechter O, Wolter P, Beuselinck B. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib. *Acta Clin Belg*. 2019;74(3):180-188.
- Tran B, Carvajal RD, Marabelle A, Patel SP, LoRusso PM, Rasmussen E, Juan G, Upreti VV, Beers C, Ngarmchamnanrith G, Schöffski P. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor related protein agonist AMG 228 in patients with advanced solid tumors. *J Immunother Cancer*. 2018;6(1):93.
- Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P,

- Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2018;29(S4):iv68-iv78. Doi: 10.1093/annonc/mdy320.
- Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkovski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2018;29(S4):iv51-iv67. doi: 10.1093/annonc/mdy321.
- Bastin J, Werbrouck E, Verbiest A, Punie K, Bechter O, Woei-A-Jin FJ, Wolter P, Wildiers H, Lerut E, Dumez H, Decallonne B, Clement P, Vanderschueren D, Albersen M, Oyen R, Schöffski P, Beuselinck B. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. *Acta Clin Belg.* 2019;74(3):169-179.
- Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Antoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organisation for Research and Treatment of Cancer phase II trial 90101 "CREATE". *Ann Oncol.* 2019;30(2):344.
- Langmans C, Cornillie J, van Cann T, Wozniak A, Hompes D, Sciot R, Debiec-Rychter M, Vandembemt I, Schöffski P. Retrospective analysis of patients with advanced liposarcoma in a tertiary referral center. *Oncol Res Treat.* 2019;42:396-403.
- Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. *Lancet Respir Med.* 2018 Jun;6(6):431-441.
- Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, Sciot R, Schöffski P. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. *Clin Cancer Res.* 2019;25(2):609-618.
- Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Beoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ. The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. *Eur J Cancer* 2018;94:156-167.
- Cortes J, Schöffski P, Littlefield BA. Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. *Cancer Treat Rev.* 2018;70:190-198.
- Schöffski P, Requilé A, van Cann T. Assessment of physician's systemic treatment preferences for patients with advanced desmoid-type fibromatosis: experience-based medicine in the absence of high-level evidence. *Oncol Res Treat.* 2018;41(4):214-219.
- Schöffski P, Cresta S, Mayer IA, Wildiers H, Damian S, Gendreau S, Rooney I, Morrissey KM, Spoerke JM, Ng VW, Singel SM, Winer E. A phase Ib study of picilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer. *Breast Cancer Research.* 2018;20:109.
- Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, Gronchi A. European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. *Clin Oncol (R Coll Radiol).* 2018 Jul;30(7):448-454.
- Dalmasso B, Hatse S, Brouwers B, Laenen A, Berben L, Kenis C, Smeets A, Neven P, Schöffski P, Wildiers H. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. *BMC Cancer.* 2018;18(1):1014.

Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2018;29(S4):iv79-iv95.

van Cann T, Comillie J, Wozniak A, Debiec-Rychter M, Sciot R, Hompes D, Vergote I, Schöffski P. Retrospective analysis of outcome of patients with metastatic leiomyosarcoma in a tertiary referral center. *Oncol Res Treat.* 2018;41(4):206-213.

Van Weehaeghe D, Gheysens O, Vandecaveye V, Schöffski P, Van Laere K, Deroose CM. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F-FDG-PET/CT. *BMC Cancer.* 2018;18(1):253.

Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, Britten CD, Dirix L, Lee KW, Taylor M, Schöffski P, Wang D, Ravaud A, Gelb AB, Xiong J, Rosen G, Gulley JL, Apolo AB. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. *Lancet Oncol.* 2018;19(1):51-64.

Schöffski P, Wozniak A, Kasper B, Aamdal S, Leahy MG, Rutkowski P, Bauer S, Gelderblom H, Italiano A, Lindner LH, Hennig I, Strauss S, Zakotnik B, Anthony A, Albiges L, Blay JY, Reichardt P, Sufliarsky J, van der Graaf WTA, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Raveloarivahy T, Collette S, Stacchiotti S. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3. European Organisation for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 "CREATE". *Ann Oncol.* 2018;29(3):758-765.

Requillé A, Clement PM, Bechter OE, Dumez H, Verbiest A, Sciot R, Hompes D, Sinnaeve F, Van Limbergen E, Schöffski P. Single-Centre experience of systemic treatment with vincristine, ifosfamide, and doxorubicin alternating with etoposide, ifosfamide, and cisplatin in adult patients with Ewing Sarcoma. *Sarcoma.* 2017;2017:1781087. Doi: 10.1155/2017/1781087. Epub 2017 Dec 28.

Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Antony A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organisation for Research and Treatment of Cancer phase II trial 90101 "CREATE". *Ann Oncol.* 2017;28(12):3000-3008. Erratum in *Ann Oncol.* 2019;30(2)344.

Quinten C, Kenis C, Hamaker M, Coolbrandt A, Brouwers B, Dal Lago L, Neven P, Vuylsteke P, Debrock G, Van Den Bulck H, Smeets A, Schöffski P, Bottomley A, Wedding U, Wildiers H. The effect of adjuvant chemotherapy on symptom burden and quality of life over time: a preliminary prospective observational study using individual data of patients aged > 70 with early stage invasive breast cancer. *J Geriatr Oncol.* 2018;9(2):152-162.

Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthony A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L. Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. *Eur J Cancer.* 2017;87:147-163.

Schöffski P, Delord JP, Brain E, Robert J, Dumez H, Gasmi J, Trouet A. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours. *Eur J Cancer.* 2017;86:240-247.

Wozniak A, Gebreyohannes YK, Debiec-Rychter M, Schöffski P. New targets and therapies for gastrointestinal stromal tumors. *Expert Rev Anticancer Ther.* 2017;17(12):1117-1129.

Beuselink B, Verbiest A, Couchy G, Job S, de Reynies A, Meiller C, Albersen M, Verkarre V, Lerut E, Méjean A, Patard JJ, Laguerre B, Rioux-Leclercq N, Schöffski P, Oudard S, Zucman-Rossie J. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. *Acta Oncol.* 2018;57(4):498-508.

Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically

- progressive medullary thyroid carcinoma. *Ann Oncol.* 2017;28(11):2813-2819.
- Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C. A precision therapy against cancers driven by KIT/PDGFRA mutations. *Sci Transl Med.* 2017 Nov 1;9(414).
- Schöffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. *Eur J Cancer.* 2017;86:296-304.
- Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. *J Clin Oncol.* 2017;35(30):3433-3439.
- Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, Coropciuc R, Politis C, Vandeweyer RO, Schoenaers J, Dumez H, Berteloot P, Neven P, Nackaerts K, Woei-A-Jin FJSH, Punie K, Wildiers H, Beuselink. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. *Acta Clin Belg.* 2018;73(2):100-109.
- Brouwers B, Fumagalli D, Brohee S, Hatse S, Govaere O, Florsi G, Van den Eynde K, Bareche Y, Schöffski P, Smeets A, Neven P, Lambrechts D, Sotiriou C, Wildiers H. The footprint of the ageing stroma in older patients with breast cancer. *Breast Cancer Res.* 2017;19(1):78.
- Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. *Lancet Oncol.* 2017;18(8):1089-1103. Erratum in *Lancet Oncol.* 2018;19(2):e78.
- Van Dievel J, Sciot R, Delcroix M, Vandeweyer RO, Debiec-Rychter M, Dewaele B, Cornillie J, Van Cann T, Meyns B, Schöffski P. Single-center experience with intimal sarcoma, an ultra-orphan, commonly fatal mesenchymal malignancy. *Oncol Res Treat.* 2017;40(6):353-359.
- Schöffski P, van Cann T, Cornillie J. Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin. *Expert Opinion on Orphan Drugs.* 2017;5(5):445-453.
- Cornillie J, Wozniak A, Pokreisz P, Casazza A, Vreys L, Wellens J, Vanleeuw U, Gebreyohannes YK, Debiec-Rychter M, Sciot R, Hompes D, Schöffski P. In Vivo antitumoral efficacy of PhAc-ALGP-Doxorubicin, an enzyme-activated doxorubicin prodrug, in patient-derived soft tissue sarcoma xenograft models. *Mol Cancer Ther.* 2017;16(8):1566-1575.
- Wawrzyniak R, Wozniak A, Gebreyohannes Y, Dykcik B, Schöffski P, Markuszewski M. Volatile organic compounds in gastrointestinal stromal tumour tissue originating from patient-derived xenografts. *J Breath Res.* 2017;11(3):037101.
- Wiemer EAC, Wozniak A, Burger H, Smid M, Floris G, Nzokirantevye A, Sciot R, Sleijfer S, Schöffski P. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: translational results of the EORTC 62052 trial. *Eur J Cancer.* 2017;75:33-40.
- Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schöffski P, Leyvraz S, Italiano A, Grünwald V, Pousa AL, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litière S, Marreaud S, van der Graaf W, Gronchi A, Verweij J; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III randomized trial on imatinib at two dose levels. *J Clin Oncol.* 2017;35(15):1713-1720.
- Wagner AJ, Kindler H, Gelderblom H, Schöffski P, Bauer S, Hohenberger P, Kopp HG, Lopez-Martin JA, Peeters M, Reichardt P, Qin A, Nippgen J, Ilaria RL, Rutkowski P. A phase II study of a human anti-PDGFRA monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors. *Ann Oncol.* 2017;28(3):541-546.
- Gebreyohannes YK, Schöffski P, Van Looy T, Wellens J, Vreys L, Cornillie J, Vanleeuw U, Aftab DT, Debiec-Rychter M, Sciot R, Wozniak A. Cabozantinib is active against human gastrointestinal stromal tumor xenografts carrying different KIT mutations. *Mol Cancer Ther.* 2016;15(12):2845-2852.
- Schöffski P, Wozniak A, Schöffski O, van Eycken L, Debiec-Rychter M. Overcoming cost implications

of mutational analysis in patients with gastrointestinal stromal tumors: a pragmatic approach. *Oncol Res Treat.* 2016;39(12):811-816.

Tolaney SM, Nechushtan H, Ron IG, Schöffski P, Awada A, Yaseenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. *Breast Cancer Res Treat.* 2016;160(2):305-312.

García-Donas J, Beuselinck B, Inglada-Pérez L, Graña O, Schöffski P, Wozniak A, Bechter O, Apellániz-Ruiz M, Leandro-García LJ, Esteban E, Castellano DE, González Del Alba A, Climent MA, Hernando S, Arranz JA, Morente M, Pisano DG, Robledo M, Rodríguez-Antona C. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. *JCI Insight.* 2016 Jul 7;1(10):e86051.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. *J Clin Oncol.* 2016;34(32):3898-3905.

Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. *Cancer.* 2016 Dec;122(24):3856-3864.

Van Keerberghen CA, Van Wambeke S, Wolter P, Schöffski P, Van Cleemput J, Van Limbergen E, Punie K, Wildiers H, Beuselinck B. A case of severe acute cardiac failure on sunitinib after left-sided thoracic radiation therapy. *Clin Genitourin Cancer.* 2017;15(1):e155-e158.

Beuselinck B, Jean-Baptiste J, Schöffski P, Couchy G, Meiller C, Rolland F, Allory Y, Joniau S, Verkarre V, Elaidi R, Lerut E, Roskams T, Patard JJ, Oudard S, Méjean A, Lambrechts D, Zucman-Rossi J. Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib. *BJU Int.* 2016 Dec;118(6):890-901.

De Block K, Vander Poorten V, Dormaar T, Nuyts S, Hauben E, Floris G, Deroose CM, Schöffski P, Clement PM. Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. *Acta Clin Belg.* 2016 Dec;71(6):383-388.

Cornillie J, van Cann T, Wozniak A, Hompes D, Schöffski P. Biology and management of clear cell sarcoma: state of the art and future perspectives. *Expert Rev Anticancer Ther.* 2016;16(8):839-845.

Bechter OE, Dumez H, Costermans J, Punie K, Hsu K, Dedieu JF, Ghuysen AF, Francesconi E, Sharma J, Liu L, Schöffski P. Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.

*Cancer Chemother Pharmacol.* 2016;78(1):83-90.

Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O, Kini Bailur J, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem GE, Wildiers H.

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. *Oncotarget.* 2016;7(21):29977-29988.

Benson C, Ray-Coquard I, Sleijfer S, Litière S, Blay JY, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla S, Gil T, Piperno-Neumann S, MARRÉAUD S, Dewji MR, van der Graaf WT. Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. *Gynecol Oncol.* 2016 Jul;142(1):89-94.

Mateo J, Olmos D, Dumez H, Poondru S, Samberg NL, Barr S, Van Tornout JM, Jie F, Sandhu S, Tan DS, Moreno V, LoRusso PM, Kaye SB, Schöffski P. A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies. *Br J Cancer.* 2016 Apr 12;114(8):889-896.

Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. *Lancet.* 2016 Apr 16;387(10028):1629-1637.

Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal

- stromal tumor treated with sunitinib in a worldwide treatment-use trial. *BM Cancer*. 2016 Jan 15;16:22.
- Schöffski P, Aftimos P, Dumez H, Deleporte A, De Block K, Costermans J, Billiet M, Meeus MA, Lee C, Schnell D, Goeldner RG, Awada A. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2016 Jan;77(1):99-108.
- Beuselinc B, Jean-Baptiste J, Couchy G, Job S, De Reynies A, Wolter P, Théodore C, Gravis G, Rousseau B, Albiges L, Joniau S, Verkarre V, Lerut E, Patard JJ, Schöffski P, Méjean A, Elaidi R, Oudard S, Zucman-Rossi J. RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. *Br J Cancer*. 2015 Nov 3;113(9):1313-1322.
- Sacré A, Barthélémy P, Korenbaum C, Burgy M, Wolter P, Dumez H, Lerut E, Loyson T, Joniau S, Oyen R, Debruyne PR, Schöffski P, Beuselinc B. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. *Acta Oncol*. 2016;55(3):329-340.
- Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 5;373(19):1814-1823.
- Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Guler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med*. 2015 Nov 5;373(19):1803-1813.
- Duffaud F, Sleijfer S, Litière S, Ray-Coquard I, Le Cesne A, Papai Z, Judson I, Schöffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT. Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. *Eur J Cancer*. 2015 Nov;51(17):2615-2623.
- Vrdoljak E, Gore M, Leyman S, Szczylik C, Kharkevich G, Schöffski P, Torday L, Mardiak J, Zhang K, Sajben P, Sella A. Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis. *Future Oncol*. 2015;11(20):2831-2840.
- Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. *Br J Cancer*. 2015 Jun 30;113(1):12-19.
- Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC. Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. *Oncologist*. 2015 Jul;20(7):823-830.
- Van Keerberghen CA, Jean-Baptiste J, Wolter P, Zucman-Rossi J, Schöffski P, Beuselinc B. Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2015 Dec;13(6):e407-410.
- Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Maki RG. Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery. *Eur J Cancer*. 2015 Aug;51(12):1611-1617.
- Viskens S, Van Veer H, Tousseyn T, Coosemans W, Decaluwe H, Naftex P, De Lyen P, Schoffski P, De Ruyscher D, Van Raemdonck D. Single-centre 20-year experience with surgical treatment of thymic tumours. *Acta Chir Belg*. 2015 Jan-Feb;115:52-61.
- Brouwers B, Dalmasso B, Hatse S, Laenen A, Kenis C, Swerts E, Neven P, Smeets A, Schöffski P, Wildiers H. Biological ageing and frailty markers in breast cancer patients. *Aging (Albany NY)*. 2015 May;7(5):319-333.
- Van Looy T, Wozniak A, Floris G, Li H, Wellens J, Vanleeuw U, Sciot R, Debiec-Rychter M, Schöffski P.
- Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. *Transl Oncol*. 2015 Apr;8(2):112-118.
- Awada A, Dumez H, Aftimos PG, Costermans J, Bartholomeus S, Forceville K, Berghmans T, Meeus MA, Cescutti J, Munzert G, Pilz K, Liu D, Schöffski P. Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity. *Invest New Drugs*.



2015 Jun;33(3):611-620.

Hristova I, Boellaard R, Vogel W, Mottaghy F, Marreaud S, Collette S, Schöffski P, Sanfilippo R, Dewji R, van der Graaf W, Oyen WJ. Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. *Eur J Nucl Med Mol Imaging*. 2015 May;42(6):848-857.

Detroyer D, Deraedt K, Schöffski P, Hauben E, Lagrou K, Naesens M, Delforge ML, Kuypers D. Resolution of diffuse skin and systemic Kaposi's sarcoma in a renal transplant recipient after introduction of everolimus: a case report. *Transpl Infect Dis*. 2015 Apr;17(2):303-307.

Kramp KH, Omer MG, Schöffski P, d'Hoore A. Sphincter sparing resection of a large obstructive distal rectal gastrointestinal stromal tumour after neoadjuvant therapy with imatinib (Glivec). *BMJ Case Rep*. 2015 Jan 8;2015. pii: bcr2014207775.

Li H, Wozniak A, Sciot R, Cornillie J, Wellens J, Van Looy T, Vanleeuw U, Stas M, Hompes D, Debiec-Rychter M, Schöffski P. Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. *Transl Oncol*. 2014 Dec;7(6):665-671.

Schöffski P, Besse B, Gauler T, de Jonge MJ, Scambia G, Santoro A, Davite C, Jannuzzo MG, Petroccione A, Delord JP. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study. *Ann Oncol*. 2015 Mar;26(3):598-607.

Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, Lewis S, Kirpekar S. Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT). *Eur J Cancer*. 2014 Dec;50(18):3153-3160.

Doussau A, Thiébaud R, Geoerger B, Schöffski P, Floquet A, Le Deley MC, Mathoulin-Pélissier S, Rizzo E, Fumoleau P, Le Tourneau C, Paoletti X. A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials. *Ann Oncol*. 2015 Feb;26(2):422-428.

Hatse S, Brouwers B, Dalmasso B, Laenen A, Kenis C, Schöffski P, Wildiers H. Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. *PLoS One*. 2014 Oct 21;9(10):e110644.

Van Looy T, Wozniak A, Floris G, Sciot R, Li H, Wellens J, Vanleeuw U, Fletcher JA, Manley PW, Debiec-Rychter M, Schöffski P. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy. *Clin Cancer Res*. 2014 Dec 1;20(23):6071-6082.

Wozniak A, Rutkowski P, Schöffski P, Ray-Coquard I, Hostein I, Schildhaus HU, Le Cesne A, Bylina E, Limon J, Blay JY, Siedlecki JA, Wardelmann E, Sciot R, Coindre JM, Debiec-Rychter M. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. *Clin Cancer Res*. 2014 Dec 1;20(23):6105-6116.

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB. Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) Collaboration Study. *Clin Cancer Res*. 2014 Nov 15;20(22):5663-5671.

Van Looy T, Gebreyohannes YK, Wozniak A, Cornillie J, Wellens J, Li H, Vanleeuw U, Floris G, Debiec-Rychter M, Sciot R, Schöffski P. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. *Clin Sarcoma Res*. 2014 Aug 10;4:10.

Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. *Leukemia*. 2015 Jan;29(1):11-19.

Schöffski P, Cornillie J, Wozniak A, Li H, Hompes D. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. *Oncol Res Treat*. 2014;37(6):355-362.

Schöffski P, Deroose CM, Gheysens O, Lips N, Slabbaert K, Vancleyenbreugel B, Moerman P, Peetermans WE. The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I. *BMC Med Imaging*. 2014 May 29;14:19.

Beuselincx B, Lambrechts D, Van Brussel T, Wolter P, Cardinaels N, Joniau S, Lerut E, Karadimou A, Couchy G, Sebe P, Ravaud A, Zerbib M, Caty A, Paridaens R, Schöffski P, Verkarre V, Berger J, Patard JJ, Zucman-Rossi J, Oudard S. Efflux pump ABCB1 single nucleotide polymorphisms and

- dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. *Acta Oncol.* 2014 Oct;53(10):1413-1422.
- Beuselinc B, Lerut E, Wolter P, Dumez H, Berkers J, Van Poppel H, Joniau S, Oyen R, De Wever L, Strijbos M, Paridaens R, Schöffski P. Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. *Clin Genitourin Cancer.* 2014 Oct;12(5):e205-214.
- Przybyl J, Sciort R, Wozniak A, Schöffski P, Vanspauwen V, Samson I, Siedlecki JA, Rutkowski P, Debiec-Rychter M. Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. *Int J Biochem Cell Biol.* 2014 Aug;53:505-513.
- Cerbone L, Van Ginderdeuren R, Van den Oord J, Fieuws S, Spileers W, Van Eenoo L, Wozniak A, Sternberg CN, Schöffski P. Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease. *Oncology.* 2014;86(3):185-189.
- Quattrone A, Wozniak A, Dewaele B, Floris G, Vanspauwen V, Van Looy T, Schöffski P, Rutkowski P, Sciort R, Debiec-Rychter M. Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. *Mod Pathol.* 2014 Nov;27(11):1510-1520.
- Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreard S, Litière S, Hermans C, Fisher C, Hogendoorn PC, dei Tos AP, van der Graaf WT; European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. *Lancet Oncol.* 2014 Apr;15(4):415-423.
- Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D. Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database. *Ann Oncol.* 2014 Jun;25(6):1222-1228.
- Schiavon G, Ruggiero A, Bekers DJ, Barry PA, Sleijfer S, Kloth J, Krestin GP, Schöffski P, Verweij J, Mathijssen RH. The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. *Eur J Cancer.* 2014 Mar;50(5):972-980.
- Boichuk S, Lee DJ, Mehalek KR, Makielski KR, Wozniak A, Seneviratne DS, Korzeniewski N, Cuevas R, Parry JA, Brown MF, Zewe J, Taguchi T, Kuan SF, Schöffski P, Debiec-Rychter M, Duensing A. Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors. *Cancer Res.* 2014 Feb 15;74(4):1200-1213.
- Blay JY, Sleijfer S, Schöffski P, Kawai A, Brodowicz T, Demetri GD, Maki RG. International expert opinion on patient-tailored management of soft tissue sarcomas. *Eur J Cancer.* 2014 Mar;50(4):679-689.
- Beuselinc B, Vano YA, Oudard S, Wolter P, De Smet R, Depoorter L, Teghom C, Karadimou A, Zucman-Rossi J, Debruyne PR, Van Poppel H, Joniau S, Lerut E, Strijbos M, Dumez H, Paridaens R, Van Calster B, Schöffski P. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. *BJU Int.* 2014 Jul;114(1):81-89.
- Smeets A, Ryckx A, Belmans A, Wildiers H, Neven P, Floris G, Schöffski P, Christiaens MR. Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer. *Springerplus.* 2013 Sep 23;2:480.
- Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. *J Clin Oncol.* 2013 Oct 10;31(29):3639-3946. Erratum in: *J Clin Oncol.* 2014 Jun 10;32(17):1864.
- Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. *Eur J Cancer.* 2013 Nov;49(17):3648-3657.
- Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, van Ijcken WF, Wozniak A, Sciort R, Rutkowski P, Schöffski P, Taguchi T, Mathijssen RH, Verweij J, Sleijfer S, Debiec-Rychter M, Wiemer EA. MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. *Br J Cancer.* 2013 Sep 17;109(6):1625-1635.
- Schöffski P, Adkins D, Blay JY, Gil T, Elias AD, Rutkowski P, Pennock GK, Youssoufian H, Gelderblom H, Willey R, Grebennik DO. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. *Eur J Cancer.* 2013 Oct;49(15):3219-3228.

Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL, Zewe JP, Wozniak A, Mehalek KR, Korzeniewski N, Seneviratne DS, Schöffski P, Debiec-Rychter M, DeCaprio JA, Duensing A. The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis.

Cancer Res. 2013 Aug 15;73(16):5120-5129.

Rutkowski P, Gronchi A, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina E, Hoiczyc M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C, van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. Ann Surg Oncol. 2013 Sep;20(9):2937-2943.

Dlaska M, Schöffski P, Bechter OE. Inter-telomeric recombination is present in telomerase-positive human cells. Cell Cycle. 2013 Jul 1;12(13):2084-2099.

Beuselink B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, de la Taille A, Tourani JM, Bigot P, Linassier C, Négrier S, Berger J, Patard JJ, Zucman-Rossi J, Oudard S. Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2013 Mar 5;108(4):887-900.

Beuselink B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinié V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis. Acta Oncol. 2014 Jan;53(1):103-112.

Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol. 2013 Jun;24(6):1513-1525.

Lagarde P, Przybyl J, Brulard C, Pérot G, Pierron G, Delattre O, Sciot R, Wozniak A, Schöffski P, Terrier P, Neuville A, Coindre JM, Italiano A, Orbach D, Debiec-Rychter M, Chibon F. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol. 2013 Feb 10;31(5):608-615.

Floris G, Wozniak A, Sciot R, Li H, Friedman L, Van Looy T, Wellens J, Vermaelen P, Deroose CM, Fletcher JA, Debiec-Rychter M, Schöffski P. A potent combination of the novel PI3K inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res. 2013 Feb 1;19(3):620-630.

Berkers J, Govaere O, Wolter P, Beuselink B, Schöffski P, van Kempen LC, Albersen M, Van den Oord J, Roskams T, Swinnen J, Joniau S, Van Poppel H, Lerut E. A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol. 2013 May;189(5):1930-1938.

Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):295-302.

Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 1;31(4):412-419.

Awada AH, Dumez H, Hendlisch A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M, Schöffski P. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):734-741.

Schiavon G, Ruggiero A, Schöffski P, van der Holt B, Bekers DJ, Eechoute K, Vandecaveye V, Krestin GP, Verweij J, Sleijfer S, Mathijssen RH. Tumor volume as an alternative response measurement for imatinib treated GIST patients. PLoS One. 2012;7(11):e48372. Erratum in: PLoS One. 2013;8(1).

Beuselink B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J, Van Poppel H, Lerut E, Debruyne P, Paridaens R, Schöffski P. Concomitant oral tyrosine

kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. *Br J Cancer*. 2012 Nov 6;107(10):1665-1671.

Penel N, Demetri GD, Blay JY, Cousin S, Maki RG, Chawla SP, Judson I, von Mehren M, Schöffski P, Verweij J, Casali P, Rodenhuis S, Schütte HJ, Cassar A, Gomez J, Nieto A, Zintl P, Pontes MJ, Le Cesne A. Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. *Ann Oncol*. 2013 Feb;24(2):537-542.

Baselga J, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. *Clin Cancer Res*. 2012 Nov 15;18(22):6364-6372.

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol*. 2012 Oct;13(10):983-92. Erratum in: *Lancet Oncol*. 2012 Nov;13(11):e464. *Lancet Oncol*. 2014 Aug;15(9):e365.

Kasper B, Ouali M, van Glabbeke M, Blay JY, Bramwell VH, Woll PJ, Hohenberger P, Schöffski P. Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931. *Eur J Cancer*. 2013 Jan;49(2):449-456.

Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N.

Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin. *Br J Cancer*. 2012 Sep 25;107(7):1025-1030.

Quattrone A, Dewaele B, Wozniak A, Bauters M, Vanspauwen V, Floris G, Schöffski P, Chibon F, Coindre JM, Sciot R, Debiec-Rychter M. Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis. *J Pathol*. 2012 Dec;228(4):565-574.

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo JR, Lopez-Vivanco G, Adler G, Canon JL, Lofts F, Castanon C, Fonseca E, Rixe O, Aparicio J, Cassinello J, Nicolson M, Mousseau M, Schalhorn A, D'Hondt L, Kerger J, Hossfeld DK, Garcia Giron C, Rodriguez R, Schöffski P, Misset JL. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. *Br J Cancer*. 2012 Jul 24;107(3):435-441.

Hollmén M, Liu P, Kurppa K, Wildiers H, Reinvall I, Vandorpe T, Smeets A, Deraedt K, Vahlberg T, Joensuu H, Leahy DJ, Schöffski P, Elenius K. Proteolytic processing of ErbB4 in breast cancer. *PLoS One*. 2012;7(6):e39413.

Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. *Eur J Cancer*. 2012 Nov;48(16):3036-3044.

Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, Emile JF, Duffaud F, Martin-Broto J, Landi B, Adenis A, Bertucci F, Bompas E, Bouché O, Leyvraz S, Judson I, Verweij J, Casali P, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. *Clin Cancer Res*. 2012 Aug 15;18(16):4458-4464. Epub 2012 Jun 20.

Schöffski P. Pazopanib in the treatment of soft tissue sarcoma. *Expert Rev Anticancer Ther*. 2012 Jun;12(6):711-723.

Smyth T, Van Looy T, Curry JE, Rodriguez-Lopez AM, Wozniak A, Zhu M, Donsky R, Morgan JG, Mayeda M, Fletcher JA, Schöffski P, Lyons J, Thompson NT, Wallis NG. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models. *Mol Cancer Ther*. 2012 Aug;11(8):1799-1808.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med*. 2012 Jul 12;367(2):107-114.

Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le

Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. *Clin Cancer Res.* 2012 Jun 1;18(11):3170-3179.

van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet.* 2012 May 19;379(9829):1879-1886.

Gore ME, Bellmunt J, Eisen T, Escudier B, Mickisch G, Patard J, Porta C, Ravaud A, Schmidinger M, Schöffski P, Sternberg CN, Szczylik C, De Nigris E, Wheeler C, Kirpekar S. Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology. *Eur J Cancer.* 2012 May;48(7):1038-1047.

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Taberero J, Soria JC, Kaye SB. Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. *J Clin Oncol.* 2012 Mar 20;30(9):996-1004.

Schöffski P, Cerbone L, Wolter P, De Wever I, Samson I, Dumez H, Clement P, Wildiers H, Stas M. Administration of 24-h intravenous infusions of trabectedin in ambulatory patients with mesenchymal tumors via disposable elastomeric pumps: an effective and patient-friendly palliative treatment option. *Onkologie.* 2012;35(1-2):14-17.

Lagarde P, Pérot G, Kauffmann A, Brulard C, Dapremont V, Hostein I, Neuville A, Wozniak A, Sciot R, Schöffski P, Aurias A, Coindre JM, Debiec-Rychter M, Chibon F. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. *Clin Cancer Res.* 2012 Feb 1;18(3):826-838.

Olmos D, Ang JE, Gomez-Roca C, Morales-Barrera R, Vulink AJ, Massard C, Kaye S; EDDN. Pitfalls and limitations of a single-centre, retrospectively derived prognostic score for phase I oncology trial participants - reply to Fussenich et al.: a new, simple and objective prognostic score for phase I cancer patients. *Eur J Cancer.* 2012 Mar;48(4):594-596.

Schöffski P, Awada A, Dumez H, Gil T, Bartholomeus S, Wolter P, Taton M, Fritsch H, Glomb P, Munzert G. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. *Eur J Cancer.* 2012 Jan;48(2):179-186.

Italiano A, Cioffi A, Coco P, Maki RG, Schöffski P, Rutkowski P, Le Cesne A, Duffaud F, Adenis A, Isambert N, Bompas E, Blay JY, Casali P, Keohan ML, Toulmonde M, Antonescu CR, Debiec-Rychter M, Coindre JM, Bui B. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. *Ann Surg Oncol.* 2012 May;19(5):1551-1559.

Schöffski P, Ray-Coquard IL, Cioffi A, Bui NB, Bauer S, Hartmann JT, Krarup-Hansen A, Grünwald V, Sciot R, Dumez H, Blay JY, Le Cesne A, Wanders J, Hayward C, Marreaud S, Ouali M, Hohenberger P; European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. *Lancet Oncol.* 2011 Oct;12(11):1045-52. Erratum in: *Lancet Oncol.* 2015 Sep;16(9):e427.

Schöffski P, Jones SF, Dumez H, Infante JR, Van Mieghem E, Fowst C, Gerletti P, Xu H, Jakubczak JL, English PA, Pierce KJ, Burris HA. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. *Eur J Cancer.* 2011 Oct;47(15):2256-2264.

Taberero J, Dirix L, Schöffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z, Knoblauch R, Zhuang SH. A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. *Clin Cancer Res.* 2011 Oct 1;17(19):6313-6321.

Floris G, Debiec-Rychter M, Wozniak A, Stefan C, Normant E, Faa G, Machiels K, Vanleeuw U, Sciot R, Schöffski P. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors. *Mol Cancer Ther.* 2011 Oct;10(10):1897-1908.

Floris G, Sciot R, Wozniak A, Van Looy T, Wellens J, Faa G, Normant E, Debiec-Rychter M, Schöffski P.

The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations. *Clin Cancer Res.* 2011 Sep 1;17(17):5604-5614.

Foulon V, Schöffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. *Acta Clin Belg.* 2011 Mar-Apr;66(2):85-96. Review.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med.* 2011 May 26;364(21):1995-2005.

Debaere D, Vander Poorten V, Nuyts S, Hauben E, Schoenaers J, Schöffski P, Clement PM. Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. *B-ENT.* 2011;7(1):1-6.

Penel N, Glabbeke MV, Mathoulin-Pelissier S, Judson I, Sleijfer S, Bui B, Schöffski P, Ouali M, Marreud S, Brouste V, Duhamel A, Hohenberger P, Blay JY. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. *Br J Cancer.* 2011 May 10;104(10):1544-1550.

Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schöffski P, Witthohn K, Lentzen H. The preclinical and clinical activity of aviscumine: a potential anticancer drug. *Eur J Cancer.* 2011 Jul;47(10):1450-1457.

Schöffski P, Dumez H, Ruijter R, Miguel-Lillo B, Soto-Matos A, Alfaro V, Giaccone G. Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies. *Cancer Chemother Pharmacol.* 2011 Dec;68(6):1397-1403.

de Jonge MJ, Dumez H, Kitzen JJ, Beuselink B, Verweij J, Courtney R, Battista A, Brega N, Schöffski P.

Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. *Eur J Cancer.* 2011 Jun;47(9):1328-1335.

Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilippo R, Casali PG, Le Cesne A, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. *Eur J Cancer.* 2011 May;47(7):1006-1012.

Schöffski P, Sweldens C, Vanderbeeken MC, Forceville K, Vandenbroucke J, Dubin M, Debiec-Rychter M, Wozniak A, Sciot R. Retroperitoneal dedifferentiated liposarcomas with production of  $\beta$ -human chorionic gonadotropin—a distinct sarcoma entity? *Onkologie.* 2011;34(3):122-125.

Quattrocelli M, Palazzolo G, Floris G, Schöffski P, Anastasia L, Orlacchio A, Vandendriessche T, Chuah MK, Cossu G, Verfaillie C, Sampaolesi M. Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs. *J Pathol.* 2011 Apr;223(5):593-603.

Wagemans J, Beuselink B, Nuyts S, Sciot R, Delaere P, Vander Poorten V, Dumez H, Hermans R, Schöffski P, Van den Bogaert W, Jorissen M, Clement PM. A case series of embryonal rhabdomyosarcoma of the head and neck in adults. *Acta Clin Belg.* 2010 Nov-Dec;65(6):404-410.

Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinar F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. *BJU Int.* 2011 Sep;108(5):679-686.

International Prognostic Factors Study Group, Lorch A, Beyer J, Bascoul-Molleivi C, Kramar A, Einhorn LH, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin KA, Lotz JP, Germa Lluch JR, Powles T, Kollmannsberger CK. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. *J Clin Oncol.* 2010 Nov 20;28(33):4906-4911.

Beuselink B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schöffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. *Ann Oncol.* 2011 Apr;22(4):794-800.

Benjamin RS, Schöffski P, Hartmann JT, Van Oosterom A, Bui BN, Duyster J, Schuetze S, Blay JY, Reichardt P, Rosen LS, Skubitz K, McCoy S, Sun YN, Stepan DE, Baker L. Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. *Cancer Chemother Pharmacol.* 2011 Jul;68(1):69-77.

Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, Baselga J, Tabernero J. A phase I dose-escalating study of ES-285, a marine sphingolipid-derived

compound, with repeat dose administration in patients with advanced solid tumors. *Invest New Drugs*. 2012 Feb;30(1):299-305.

Wozniak A, Floris G, Debiec-Rychter M, Sciot R, Schöffski P. Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies.

*Cancer Invest*. 2010 Oct;28(8):839-848.

Dewaele B, Floris G, Finalet-Ferreiro J, Fletcher CD, Coindre JM, Guillou L, Hogendoorn PC, Wozniak A, Vanspauwen V, Schöffski P, Marynen P, Vandenberghe P, Sciot R, Debiec-Rychter M. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. *Cancer Res*. 2010 Sep 15;70(18):7304-7314.

Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, Reynoso D, McMahon J, Taguchi T, Floris G, Debiec-Rychter M, Schöffski P, Trent JA, Debnath J, Rubin BP. Autophagy inhibition and antimetabolites promote cell death in gastrointestinal stromal tumor (GIST). *Proc Natl Acad Sci U S A*. 2010 Aug 10;107(32):14333-14338.

Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21 Suppl 5:v98-102. Erratum in: *Ann Oncol*. 2011 Jan;22(1):243.

Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21 Suppl 5:v204-213.

Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21 Suppl 5:v198-203. Erratum in: *Ann Oncol*. 2010 Aug;21(8):1736.

Schöffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, Hollaender N, Jappe A, Demetri GD. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. *Ann Oncol*. 2010 Oct;21(10):1990-1998.

Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapon J, Allgeier A, Bogaerts J, Lacombe D. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). *Eur J Cancer*. 2010 Aug;46(12):2206-2215.

Schöffski P, Garfield DH, Hercbergs A, Wolter P. Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors. *Br J Cancer*. 2010 Apr 13;102(8):1309-10; author reply 1311.

Salas S, Chibon F, Noguchi T, Terrier P, Ranchere-Vince D, Lagarde P, Benard J, Forget S, Blanchard C, Dômont J, Bonvalot S, Guillou L, Leroux A, Mechine-Neuville A, Schöffski P, Laë M, Collin F, Verola O, Carbonnelle A, Vescovo L, Bui B, Brouste V, Sobol H, Aurias A, Coindre JM. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. *Genes Chromosomes Cancer*. 2010 Jun;49(6):560-568.

Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schöffski P. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? *Thyroid*. 2010 Mar;20(3):317-322.

Vulsteke C, Dierickx D, Verbeke E, Wolter P, Thomas J, Schöffski P. Rituximab-induced fatal interstitial pneumonitis: case report. *Leuk Lymphoma*. 2010 Mar;51(3):546-548.

Manner J, Radlwimmer B, Hohenberger P, Mössinger K, Küffer S, Sauer C, Belharazem D, Zettl A, Coindre JM, Halleemann C, Hartmann JT, Katenkamp D, Katenkamp K, Schöffski P, Sciot R, Wozniak A, Lichter P, Marx A, Ströbel P. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. *Am J Pathol*. 2010 Jan;176(1):34-39.

Wolter P, Schöffski P. Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. *Acta Oncol*. 2010;49(1):13-23.

Dumez H, Gallardo E, Culine S, Galceran JC, Schöffski P, Droz JP, Extremera S, Szyldergemajn S, Fléchon A. Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium. *Mar Drugs*. 2009 Sep 16;7(3):451-463.

Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. *Clin Cancer Res*.

2009 Sep 15;15(18):5869-5877.

Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, Schöffski P, Poveda A.

Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. *Semin Oncol.* 2009 Aug;36(4):302-311.

Reichardt P, Hogendoorn PC, Tamborini E, Loda M, Gronchi A, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. *Semin Oncol.* 2009 Aug;36(4):290-301.

Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schöffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. *J Clin Oncol.* 2009 Aug 20;27(24):3969-3974.

Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. *Lancet Oncol.* 2009 Aug;10(8):757-763.

Floris G, Debiec-Rychter M, Sciot R, Stefan C, Fieuws S, Machiels K, Atadja P, Wozniak A, Faa G, Schöffski P. High efficacy of panobinostat towards human gastrointestinal stromal tumors in a xenograft mouse model. *Clin Cancer Res.* 2009 Jun 15;15(12):4066-4076.

Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. *Oncologist.* 2009 Jun;14(6):559-70. doi: 10.1634/theoncologist.2009-0010. Epub 2009 May 27. Review.

Montemurro M, Schöffski P, Reichardt P, Gelderblom H, Schütte J, Hartmann JT, von Moos R, Seddon B, Joensuu H, Wendtner CM, Weber E, Grünwald V, Roth A, Leyvraz S. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. *Eur J Cancer.* 2009 Sep;45(13):2293-2297.

Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwier A, van Glabbeke M, Verweij J, Blay JY. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). *J Clin Oncol.* 2009 Jul 1;27(19):3126-3132.

Schöffski P, Bukowski R, Flodgren P, Ravaud A. Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. *Ann Oncol.* 2009 May;20 Suppl 1:i25-i30.

Schöffski P, Guillem V, Garcia M, Rivera F, Tabernero J, Cullell M, Lopez-Martin JA, Pollard P, Dumez H, del Muro XG, Paz-Ares L. Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma. *Mar Drugs.* 2009;7(1):57-70.

Schöffski P, Wolter P, Vandenborre K, Haustermans K. Clinical response of renal cell carcinoma to dexamethasone. *Cancer Invest.* 2009 Jun;27(5):529-532.

Wolter P, Beuselink B, Pans S, Schöffski P. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. *Acta Oncol.* 2009;48(4):621-624.

Huebner G, Link H, Kohne CH, Stahl M, Kretschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schöffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, Aldaoud A, Jahn A; German CUP Study Group. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.

*Br J Cancer.* 2009 Jan 13;100(1):44-49.

Garfield DH, Wolter P, Schöffski P, Hercbegs A, Davis P. Documentation of thyroid function in clinical studies with sunitinib: why does it matter? *J Clin Oncol.* 2008 Nov 1;26(31):5131-2; author reply 5132-5133.

Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, Wozniak A, Schöffski P, Marynen P, Debiec-Rychter M. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.

*Clin Cancer Res.* 2008 Sep 15;14(18):5749-5758.

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. *Br J Cancer.* 2008 Aug 5;99(3):448-



454.

Schöffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, Van Oosterom AT. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. *Expert Opin Pharmacother*. 2008 Jun;9(9):1609-1618.

Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zanti N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I. Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial. *J Clin Oncol*. 2008 May 10;26(14):2285-2291.

Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii89-93.

Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii35-38.

Ray-Coquard I, Le Cesne A, Whelan JS, Schöffski P, Bui BN, Verweij J, Marreaud S, van Glabbeke M, Hogendoorn P, Blay JY. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. *Oncologist*. 2008 Apr;13(4):467-473.

Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schöffski P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. *Invest New Drugs*. 2008 Oct;26(5):483-488.

Hoeben A, Schöffski P, Debiec-Rychter M. Clinical implications of mutational analysis in gastrointestinal stromal tumours. *Br J Cancer*. 2008 Feb 26;98(4):684-688.

Brown B, Diamantopoulos A, Bernier J, Schöffski P, Hieke K, Mantovani L, Launois R, Griebisch I, Robinson P. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. *Value Health*. 2008 Sep-Oct;11(5):791-799.

Schöffski P, Wolter P, Clement P, Sciot R, De Wever I, Wozniak A, Stefan C, Dumez H. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. *Future Oncol*. 2007 Aug;3(4):381-392. Review.

Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC; EORTC New Drug Development Group. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. *Cancer Chemother Pharmacol*. 2008 Apr;61(4):579-585. Epub 2007 May 23.

Huygh G, Clement PM, Dumez H, Schöffski P, Wildiers H, Selleslach J, Jimeno JM, Wever ID, Sciot R, Duck L, Van Oosterom AT. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. *Sarcoma*. 2006;2006:56282. Epub 2006 Dec 31.

Wolter P, Dumez H, Schöffski P. Sunitinib and hypothyroidism. *N Engl J Med*. 2007 Apr 12;356(15):1580; author reply 1580-1581.

Debruyne PR, Dumez H, Demey W, Gillis L, Sciot R, Schöffski P. Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to tofosfamide. *Onkologie*. 2007 Apr;30(4):201-204. Epub 2007 Mar 23.

Prenen H, Dumez H, Stefan C, Hoeben A, Wouters C, Van Lierde MA, Sciot R, van Oosterom AT, Peeters M, Polus M, Duck L, Gil T, Schöffski P. Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial. *Acta Gastroenterol Belg*. 2006 Oct-Dec;69(4):367-371.

Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schöffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY; EORTC Soft Tissue and Bone Sarcoma Group. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II-study of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer*. 2007 Apr;43(6):1017-1022. Epub 2007 Mar 1.

de Raedt T, Cools J, Debiec-Rychter M, Brems H, Mentens N, Sciot R, Himpens J, de Wever I, Schöffski P, Marynen P, Legius E. Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. *Gastroenterology*. 2006 Dec;131(6):1907-1912.

Guetens G, Prenen H, De Boeck G, van Oosterom A, Schöffski P, Highley M, de Bruijn EA. Simultaneous determination of AMN107 and Imatinib (Gleevec, Glivec, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2007 Feb 1;846(1-2):341-345. Epub 2006 Sep 7.

Paoletti X, Baron B, Schöffski P, Fumoleau P, Lacombe D, Marreaud S, Sylvester R. Using the

- continual reassessment method: lessons learned from an EORTC phase I dose finding study. *Eur J Cancer*. 2006 Jul;42(10):1362-1368. Epub 2006 Jun 5.
- Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schöffski P, Van Oosterom A, Marynen P, Debiec-Rychter M. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. *Clin Cancer Res*. 2006 Apr 15;12(8):2622-2627.
- Prenen H, Deroose C, Vermaelen P, Sciot R, Debiec-Rychter M, Stroobants S, Mortelmans L, Schöffski P, Van Oosterom A. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography. *Anticancer Res*. 2006 Mar-Apr;26(2A):1247-1252.
- Prenen H, Guetens G, de Boeck G, Debiec-Rychter M, Manley P, Schoffski P, van Oosterom AT, de Bruijn E. Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. *Pharmacology*. 2006;77(1):11-16. Epub 2006 Mar 8.
- Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, Wolter P, Joniau S, Roskams T, Van Poppel H.
- Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. *Ann Oncol*. 2006 Aug;17(8):1185-1196. Epub 2006 Jan 17. Review.
- Folprecht G, Lutz MP, Schöffski P, Seufferlein T, Nolting A, Pollert P, Köhne CH. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. *Ann Oncol*. 2006 Mar;17(3):450-456. Epub 2005 Nov 22.
- Efficace F, Bottomley A, Coens C, Van Steen K, Conroy T, Schöffski P, Schmoll H, Van Cutsem E, Köhne CH. Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? *Eur J Cancer*. 2006 Jan;42(1):42-9. Epub 2005 Nov 18. Erratum in: *Eur J Cancer*. 2007 Feb;43(3):633.
- Twelves CJ, Butts CA, Cassidy J, Conroy T, Braud Fd, Diaz-Rubio E, Tabernero JM, Schoffski P, Figer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. *Clin Colorectal Cancer*. 2005 Jul;5(2):101-107.
- Beutel G, Glen H, Schöffski P, Chick J, Gill S, Cassidy J, Twelves C. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. *Clin Cancer Res*. 2005 Aug 1;11(15):5487-5495.
- Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schöffski P, Schleicher J, Mayer F, Teichmann R, Kanz L, Bokemeyer C. Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. *Ann Surg*. 2005 Aug;242(2):260-266.
- Guetens G, Prenen H, De Boeck G, Van Dongen W, Esmans E, Lemièrre F, van Oosterom AT, Schöffski P, de Bruijn EA. Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry. *J Chromatogr A*. 2005 Jul 29;1082(1):2-5.
- Adler M, Langer M, Witthohn K, Wilhelm-Ogunbiyi K, Schöffski P, Fumoleau P, Niemyer CM. Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples. *J Pharm Biomed Anal*. 2005 Oct 4;39(5):972-982. Epub 2005 Jun 27.
- Schöffski P, Breidenbach I, Krauter J, Bolte O, Stadler M, Ganser A, Wilhelm-Ogunbiyi K, Lentzen H. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. *Eur J Cancer*. 2005 Jul;41(10):1431-1438.
- Smyth JF, Aamdal S, Awada A, Dittrich C, Caponigro F, Schöffski P, Gore M, Lesimple T, Djurasinovic N, Baron B, Ravic M, Fumoleau P, Punt CJ; EORTC New Drug Development and Melanoma Groups. Phase II study of E7070 in patients with metastatic melanoma. *Ann Oncol*. 2005 Jan;16(1):158-161.
- Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J. A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors. *Cancer Chemother Pharmacol*. 2005 Feb;55(2):136-142. Epub 2004 Sep 29.
- Grünwald V, Bolte O, Wiebe S, Ganser A, Schöffski P. Acral necrosis after inadequate excessive administration of bleomycin in a testicular cancer patient. *Onkologie*. 2005 Jan;28(1):41-43.
- Schöffski P, Riggert S, Fumoleau P, Campone M, Bolte O, Marreaud S, Lacombe D, Baron B, Herold M, Zwierzina H, Wilhelm-Ogunbiyi K, Lentzen H, Twelves C; European Organization for Research and Treatment of Cancer New Drug Development Group. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. *Ann Oncol*. 2004 Dec;15(12):1816-1824.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, Figer A, Grossmann J, Sawada N, Schöffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. *J Clin Oncol*. 2004 Jun 1;22(11):2084-2091.

Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schöffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifamib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol*. 2004 Apr 15;22(8):1430-1438.

Schöffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. *Anticancer Drugs*. 2004 Feb;15(2):85-106. Review.

Tacke F, Schöffski P, Luedde T, Meier PN, Ganser A, Manns MP, Trautwein C. Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. *Scand J Gastroenterol*. 2004 Mar;39(3):259-266.

Schöffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. *Ann Oncol*. 2004 Apr;15(4):671-679.

Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C; German Testicular Cancer Study Group. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. *J Clin Oncol*. 2003 Nov 15;21(22):4083-4091. Epub 2003 Oct 20.

Briasoulis E, Pavlidis N, Terret C, Bauer J, Fiedler W, Schöffski P, Raoul JL, Hess D, Selvais R, Lacombe D, Bachmann P, Fumoleau P. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. *Eur J Cancer*. 2003 Nov;39(16):2334-2340.

Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H, Lichnitscher M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ; European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. *J Clin Oncol*. 2003 Oct 15;21(20):3721-3728. Epub 2003 Sep 8.

Tacke F, Schöffski P, Trautwein C, Luedde T, Ganser A, Manns MP, von Depka M. Plasma P-selectin levels are elevated in patients with chronic liver disease. *Blood Coagul Fibrinolysis*. 2003 Jun;14(4):319-325.

Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J, Fumoleau P; EORTC Early Clinical Studies Group. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). *Eur J Cancer*. 2003 Jun;39(9):1264-1270.

Tacke F, Brabant G, Kruck E, Horn R, Schöffski P, Hecker H, Manns MP, Trautwein C. Ghrelin in chronic liver disease. *J Hepatol*. 2003 Apr;38(4):447-454.

Van den Brande J, Schöffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Köhler K, Reinke F, Wanders J, de Boer RF, Vermorken JB, Fumoleau P. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. *Br J Cancer*. 2003 Mar 10;88(5):648-653.

Kollmannsberger C, Schleucher N, Rick O, Metzner B, Hartmann JT, Schöffski P, Beyer J, Casper J, Sosada M, Schmoll HJ, Böhlke I, Meisner C, Kanz L, Bokemeyer C. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support. *Eur J Cancer*. 2003 Apr;39(6):775-782.

Schoemaker NE, Mathôt RA, Schöffski P, Rosing H, Schellens JH, Beijnen JH. Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule. *Cancer Chemother Pharmacol*. 2002 Dec;50(6):514-517.

Bokemeyer C, Oechsle K, Hartmann JT, Schöffski P, Schleucher N, Metzner B, Schleicher J, Kanz L. Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. *Br J Cancer*. 2002 Nov 4;87(10):1066-1071.

Schöffski P. New drugs for treatment of gastric cancer. *Ann Oncol*. 2002;13 Suppl 4:13-22. Review.

Volk J, Sel S, Ganser A, Schöffski P. Tumor cell-based vaccination in renal cell carcinoma: rationale.

- approaches, and recent clinical development. *Curr Drug Targets*. 2002 Oct;3(5):401-408.
- Schoemaker NE, Rosing H, Jansen S, Schöffski P, Rizzo J, Schellens JH, Beijnen JH. Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2002 Aug 5;775(2):231-237.
- Tacke F, Trautwein C, Zhao S, Andreeff M, Manns MP, Ganser A, Schöffski P. Quantification of hepatic thrombopoietin mRNA transcripts in patients with chronic liver diseases shows maintained gene expression in different etiologies of liver cirrhosis. *Liver*. 2002 Jun;22(3):205-212.
- Schöffski P. Patient preference for oral chemotherapy. *Krankenpfl J*. 2002;40(1-2):40-41. German.
- Schöffski P, Tacke F, Trautwein C, Martin MU, Caselitz M, Hecker H, Manns MP, Ganser A. Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease. *Liver*. 2002 Apr;22(2):114-120.
- Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schöffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. *J Clin Oncol*. 2002 Apr 15;20(8):2031-2037.
- Schöffski P, Herr A, Vermorken JB, Van den Brande J, Beijnen JH, Rosing H, Volk J, Ganser A, Adank S, Botma HJ, Wanders J. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue. *Eur J Cancer*. 2002 Apr;38(6):807-813.
- Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. *Ann Oncol*. 2002 Feb;13(2):308-317.
- Borner MM, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. *Eur J Cancer*. 2002 Feb;38(3):349-358.
- Grünwald V, Le Blanc S, Karstens JH, Weihkopf T, Kuske M, Ganser A, Schöffski P. Metastatic malignant ameloblastoma responding to chemotherapy with paclitaxel and carboplatin. *Ann Oncol*. 2001 Oct;12(10):1489-91.
- Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. *Eur J Nucl Med*. 2001 Dec;28(12):1751-1757.
- Tacke F, Schöffski P, Trautwein C, Manns MP, Ganser A, von Depka M. Tissue factor and thrombomodulin levels are correlated with stage of cirrhosis in patients with liver disease. *Blood Coagul Fibrinolysis*. 2001 Oct;12(7):539-545.
- Volk J, Reinke F, van Kuilenburg AB, van Gennip AH, Schlichting C, Ganser A, Schöffski P. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. *Ann Oncol*. 2001 Apr;12(4):569-71.
- Schöffski P, Wanders J, Verweij J, Fumoleau P; EORTC Early Clinical Studies Group. Docetaxel and cisplatin in head and neck cancer. *Ann Oncol*. 2000 Dec;11(12):1617.
- Schöffski P, Seeland G, Engel H, Grünwald V, Paul H, Merkle K, Kowalski R, Ganser A. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. *Ann Oncol*. 2000 Jun;11(6):729-734.
- Schöffski P, Ganser A, Pascheberg U, Büsche G, Gaede B, Hertenstein B. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. *Ann Hematol*. 2000 Feb;79(2):95-98.
- Schöffski P, Hagedorn T, Grünwald V, Paul H, Merkle K, Kowalski R, Ganser A. Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours. *J Cancer Res Clin Oncol*. 2000 Jan;126(1):41-47.
- Schöffski P, Chollet P, Ganser A, Wiese KH, Rambusch E, de Vries MJ, Hanauske A. Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group. *Ann Oncol*. 1999 Sep;10(9):1117-1120.
- Ravaud A, Borner M, Schellens JH, Geoffrois L, Schöffski P, Wanders J, Hanauske AR. UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer. *Oncology (Williston Park)*. 1999 Jul;13(7 Suppl 3):61-63.
- Tacke F, Schöffski P, Trautwein C, Martin MU, Stangel W, Seifried E, Manns MP, Ganser A, Petersen

D.

Endogenous serum levels of thrombopoietic cytokines in healthy whole-blood and platelet donors: implications for plateletpheresis. *Br J Haematol.* 1999 May;105(2):511-513.

Schöffski P, Tacke F, Ganser A, Trautwein C, Martin MU, Petersen D. Plateletpheresis does not lead to a lasting increase in serum thrombopoiesis growth factor levels. *Transfusion.* 1999 Apr;39(4):429-431.

Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. *J Clin Oncol.* 1999 Feb;17(2):512-516.

Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. *Ann Oncol.* 1999 Jan;10(1):119-122.

Schöffski P, Wehkopf T, Ganser A. Advanced head and neck cancer and clinical experience of an effective new agent: docetaxel. *Anticancer Res.* 1998 Nov-Dec;18(6B):4751-4756. Review.

Kollmannsberger C, Beyer J, Droz JP, Harstrick A, Hartmann JT, Biron P, Fléchon A, Schöffski P, Kuczyk M, Schmoll HJ, Kanz L, Bokemeyer C. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. *J Clin Oncol.* 1998 Oct;16(10):3386-3391.

Schöffski P, Freund M, Wunder R, Petersen D, Köhne CH, Hecker H, Schubert U, Ganser A.

Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. *BMJ.* 1998 Aug 8;317(7155):379-384.

Bokemeyer C, Harstrick A, Beyer J, Metzner B, Rütger U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schöffski P, Kühner I, Illiger HJ, Kempf B, Reichle A, Föller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchner H, Pflüger KH, Ostermann H, Kanz L, Schmoll HJ. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. *Semin Oncol.* 1998 Apr;25(2 Suppl 4):24-32; discussion 45-8.

Nölle C, Stöver T, Schöffski P, Lenarz T. Interesting case no. 9. Esthesioneuroblastoma (olfactory neuroblastoma). *Laryngorhinootologie.* 1998 Jan;77(1):61-64.

Köhne CH, Harstrick A, Hiddemann W, Schöffski P, Wilke H, Bokemeyer C, Dörken B, Schmoll HJ.

Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study. *Eur J Cancer.* 1997 Oct;33(11):1896-1899.

Köhne CH, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll HJ. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. *J Clin Oncol.* 1998 Feb;16(2):418-426.

Bokemeyer C, Köhmann O, Tischler J, Weissbach L, Rätz U, Haupt A, Schöffski P, Harstrick A, Schmoll HJ. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. *Ann Oncol.* 1996 Dec;7(10):1015-1021.

Köhne CH, Wilke H, Schöffski P, Schmoll HJ. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer. *J Infus Chemother.* 1996 Fall;6(4):206-210.

Link H, Diedrich H, Arseniev L, Stoll M, Ebell W, Freund M, Tischler J, Casper J, Hübner G, Schöffski P, Diehl S, Goes A, Jacobs R, Kadar J, Stangel W, Müller R, Rittmann KL, Wildfang I, Bucsky P, Bettoni C, Schmidt RE, Riehm H, Poliwoda H. 10 years transplantation of bone marrow and hematopoietic stem cells in adults at the Hannover Medical School. *Med Klin (Munich).* 1996 Apr 12;91 Suppl 3:3-17.

Verweij J, Wanders J, Gil T, Schöffski P, Catimel G, te Velde A, de Mulder PH. Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group. *Br J Cancer.* 1996 Feb;73(3):400-402.

Creemers GJ, Wanders J, Gamucci T, Vallentin S, Dirix LY, Schöffski P, Hudson I, Verweij J. Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group. *Ann Oncol.* 1995 Oct;6(8):844-846.

Köhne CH, Wilke H, Hecker H, Schöffski P, Käufer C, Rauschecker H, Andreesen R, Ohl U, Lange

HJ, Klaassen U, et al. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO). *Ann Oncol.* 1995 May;6(5):461-466.

Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, van Meerbeek J, Wanders J, Franklin HR, Kaye S.

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). *Br J Cancer.* 1994 Aug;70(2):384-387.

Köhne-Wömpner CH, Schöffski P, Schmoll HJ. Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation. *Ann Oncol.* 1994;5 Suppl 3:97-104.

Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, Kaye SB. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. *Eur J Cancer.* 1994;30A(8):1058-1060.

Bokemeyer C, Kuczyk M, Schöffski P, Schmoll HJ. Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. *J Urol.* 1993 Nov;150(5 Pt 1):1509-1510.

Bokemeyer C, Frank B, Schoffski P, Poliwoda H, Schmoll H. Phantom sensations after orchiectomy for testicular cancer. *Int J Oncol.* 1993 Apr;2(4):633-636.

Harstrick A, Bokemeyer C, Schmoll HJ, Köhne-Wömpner CH, Knipp H, Schöffski P, Anagnostou J, Wipperfurth B, Neumann S, Poliwoda H. A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. *Cancer Chemother Pharmacol.* 1993;31 Suppl 2:S217-221.

Bokemeyer C, Schmoll HJ, Schöffski P, Harstrick A, Bading M, Poliwoda H. Bilateral testicular tumours: prevalence and clinical implications. *Eur J Cancer.* 1993;29A(6):874-876.

Bokemeyer C, Harstrick A, Schöffski P, Schmoll HJ, Poliwoda H. Germ-cell tumors of the testis. The epidemiological and etiological aspects. *Dtsch Med Wochenschr.* 1992 Oct 2;117(40):1532-1537.

Bokemeyer C, Harstrick A, Schmoll HJ, Köhne-Wömpner CH, Schöffski P, Poliwoda H. Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. *Ann Oncol.* 1992 Jun;3(6):487-488.

Schmoll HJ, Köhne-Wömpner CH, Hiddemann W, Knipp H, Wilke H, Bodenstein H, Schöffski P, Bokemeyer C, Lohrmann HP, Preiss J, et al. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial. *Semin Oncol.* 1992 Apr;19(2 Suppl 3):191-196.

## Projects

### Memberships

American Association for Cancer Research (AACR)  
 American Society of Clinical Oncology (ASCO)  
 American Society of Hematology (ASH), until 2010  
 American Thyroid Association (ATA)  
 Arbeitsgemeinschaft Internistische Onkologie (AIO), until 2013  
 Belgian Society of Medical Oncology (BSMO)  
 Board Member Belgian Association of Phase-I Units (BAPU), until 2010  
 Deutsche Gesellschaft für Hämatologie/Onkologie (DGHO)  
 Deutscher Hochschulverband (DHV)  
 Deutsche Krebsgesellschaft Sektion B (DKG), until 2013  
 EORTC Gastrointestinal Tumours Study Group (GITSG), until 2004  
 EORTC Soft Tissue and Bone Sarcoma Group (STBSG)  
 EORTC Endocrine Tumours Task Force (EnTF), Founder  
 The Histiocyte Society, until 2018  
 Japanese Society of Medical Oncology (JSMO)  
 Kompetenznetzwerk Akute und Chronische Leukämie, until 2004  
 Sarcoma Alliance for Research Through Collaboration (SARC)  
 Sarcoma Foundation of America

Koninklijke Academie voor Geneeskunde van België (KAGB) – probationary member until 22/10/2016; member as of 22/10/2016

World Sarcoma Network

Commissie Tegemoetkoming Geneesmiddelen (CTG) – substitute member since 2019

#### Other Relevant Information

Work package leader:

2005 – 2011, Connective Tissue Network of Excellence EU, 6th Framework program, EU, Brussels, Belgium

Appointment as trustee:

Since 2006, Kankerfonds G. van der Schueren, KUL, Leuven, Belgium

Secretary general:

2006 – 2009, European Organization for Research and Treatment of Cancer, Brussels, Belgium

Appointment as member:

2007-2011, Klinische Onderzoeks- en Opleidingsraad, UZL, Leuven, Belgium

Appointed as member:

Since 2007, Erkenningscommissie bijzondere beroepstitel Medische Oncologie, Brussels, Belgium

Member of board of directors:

2008 – 2011, Connective Tissue Oncology Society (CTOS)

Recognition as medical oncologist:

28.02.2008, Federale Overheidsdienst Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu, Brussels, Belgium

Appointed as member:

Since 2008, International Scientific Council, Cancéropôle Île-de-France, Paris, France

Member scientific program committee:

2008 – 2010, American Society of Clinical Oncology, Annual Meeting scientific committee

Recognition as training supervisor (stagemeester) medical oncology:

22.09.2008, Federale Overheidsdienst Volksgezondheid, Veiligheid van de Voedselketen en Leefmilieu Brussels, Belgium

Member, international scientific advisory board:

Since 2010, Ontario Institute for Cancer Research, Toronto, Canada

Appointed as chairman clinical research division:

2009 – 2012, European Organization for Research and Treatment of Cancer, Brussels, Belgium

Appointed as member, board of directors:

2010 - 2014, European Cancer Organization (ECCO), Brussels, Belgium

Promotion to extraordinary (full) professorship:

01.10.2010, Academic title “Buitengewoon Hoogleraar”, KUL, Leuven, Belgium

Workshop director:

2011 – 2014, ECCO-AACR-ASCO-EORTC Workshop on Methods in Clinical Cancer Research, Flims, Switzerland

Appointed as member, scientific council:

Since 2010, Journal “Onkologie”, Karger, Basel, Switzerland

Appointed as member, editorial board:

Since 2010, Journal “Clinical Sarcoma Research”

Appointed as trustee:

Since 2011, Bart Verbeeck Fonds, KUL, Leuven, Belgium

Member, scientific advisory panel:

Since 2012, CRT Pioneer Fund/6th Element Capital, London, United Kingdom

Appointed as trustee:

Since 2012, Hans en Els Vandamme Fonds for personalized oncology, KUL, Leuven, Belgium

Deputy member Paritair Comité medische Oncologie:

Since 2012, Rijksinstituut voor ziekte- en invaliditeitsverzekering, Brussels, Belgium

Advisory function:

Since 2013, Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Universitätsklinik RWTH Aachen, Germany

Appointed as member:

Since 2013, Belgian Royal Academy of Medicine, Brussels, Belgium

Appointed as Member:

Since 2013, Vaste Commissie Wetenschappelijk Onderzoek in de Biomedische Disciplines, Belgian Royal Academy of Medicine, Brussels, Belgium

Appointed as member editorial board:

Since 2014, Journal "Oncology Research and Treatment", Karger, Basel, Switzerland

External Scientific Advisor:

Since 2014, Memorial Sloan-Kettering sarcoma Specialized Programs of Research Excellence (SPORE) – Memorial Sloan-Kettering Cancer Center/U.S. National Cancer Institute translational research program, New York, Bethesda, United States

Appointed as member board of directors:

2015-2018, European Organization for Research and Treatment of Cancer, Brussels, Belgium

Appointed as Secretary General:

2015 – 2018, European Organization for Research and Treatment of Cancer, Brussels, Belgium (EORTC)

Member Programme Committee

2015 – 2019, Nederlandse Oncologiedagen, The Netherlands

Full professorship:

01.09.2015, Academic title "Gewoon Hoogleraar", KUL, Leuven, Belgium

Full member:

22.06.2016, European Network for Rare Adult Cancers (EURACAN), European call for European Reference Network, European Commission, Brussels, Belgium

Member:

21.11.2016, Amcure GmbH, member Study Monitoring Committee, study AMC303-01 (EudraCT no.: 2016-001358-16)

Chair:

11.2016, Adaptimmune, Chair Data Safety Monitoring Board, study ADP-0011-0066, IND Number 14603

Visiting Professorship:

06.2016, Leidens Universitair Medisch Centrum, Leiden, The Netherlands

Laureate:

06.2017, Jaap De Graeff penning, Leiden, The Netherlands

Member:

01.2019, Commissie Tegemoetkoming Geneesmiddelen RIZIV (Commission Drug Reimbursement of the National Institute for Health and Invalidity Insurance)

Member:

05.06.2019, American Society of Clinical Oncology (ASCO), Advisory Committee

Awards

Merit Award:

1996, American Society of Clinical Oncology, ASCO Annual Meeting, Philadelphia, United States

Merit Award:

1996, American Society of Clinical Oncology, ASCO Annual Meeting, Philadelphia, United States



## Outstanding Abstract Award:

1997, European Congress of Clinical Microbiology and Infectious Diseases Lausanne, Switzerland

## Scientific Award:

1998, Arbeitsgemeinschaft Internistische Onkologie der Deutschen Krebsgesellschaft, Berlin, Germany

## Abstract Award:

1999, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Washington, United States

## Laureate:

07.11.2014, Oswald Vander Veken Award for Tumours of the Locomotor Apparatus, Fonds Wetenschappelijk Onderzoek (FWO), Brussels, Belgium

## Best Abstract:

12.10.2015, DGHO Annual Meeting 2015, Basel, Switzerland

## Laureate:

06.2017, Jaap De Graeff penning, Leiden, The Netherlands

## Abstract award:

02.08.2019: ASCO Breakthrough award 2019 – “Establishment of a tissue microarray (TMA) platform as an efficient tool for soft tissue sarcoma (STS) research available for collaboration”